Associated Papers
α-Synuclein at the Presynaptic Axon Terminal as a Double-Edged Sword.
Tan LY et al.
Biomolecules, 2022
Low-Expressing Synucleinopathy Mouse Models Based on Oligomer-Forming Mutations and C-Terminal Truncation of α-Synuclein.
Martinez Hernandez A et al.
Frontiers in Neuroscience, 2021
Genetically engineered animal models of Parkinson's disease: From worm to rodent.
Breger LS et al.
The European Journal of Neuroscience, 2019
Parkinson's Disease Associated α-Synuclein Familial Mutants Promote Dopaminergic Neuronal Death in Drosophila melanogaster.
Mohite GM et al.
Acs Chemical Neuroscience, 2018
Systematic comparison of the effects of alpha-synuclein mutations on its oligomerization and aggregation.
Lázaro DF et al.
Plos Genetics, 2014
Accumulation of oligomer-prone α-synuclein exacerbates synaptic and neuronal degeneration in vivo.
Rockenstein E et al.
Brain : a Journal of Neurology, 2014
The many faces of α-synuclein: from structure and toxicity to therapeutic target.
Lashuel HA et al.
Nature Reviews. Neuroscience, 2013
Aggregate clearance of α-synuclein in Saccharomyces cerevisiae depends more on autophagosome and vacuole function than on the proteasome.
Petroi D et al.
The Journal of Biological Chemistry, 2012
Supramolecular non-amyloid intermediates in the early stages of α-synuclein aggregation.
Fauerbach JA et al.
Biophysical Journal, 2012
New animal models of Parkinson's disease.
Dehay B et al.
Movement Disorders : Official Journal of the Movement Disorder Society, 2011
Characterization of hydrophobic residue requirements for alpha-synuclein fibrillization.
Waxman EA et al.
Biochemistry, 2009
Select a paper to view details